# Validation of Hemoglobin A1c in Patients With Inflammatory Arthritis Treated With Sulfasalazine

> **NCT07416656** · — · NOT_YET_RECRUITING · sponsor: **Klavs Würgler Hansen** · enrollment: 75 (estimated)

## Conditions studied

- Inflammatory Arthritis
- Diabetes (DM)
- Rheumatoid Arthritis (RA)
- Type 1 Diabetes Mellitus
- Type 2 Diabetes (T2DM)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07416656
- **Lead sponsor:** Klavs Würgler Hansen
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02
- **Primary completion:** 2026-06
- **Final completion:** 2026-09
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07416656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07416656, "Validation of Hemoglobin A1c in Patients With Inflammatory Arthritis Treated With Sulfasalazine". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07416656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*